As filed with the Securities and Exchange Commission on October 11, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Upstream Bio, Inc.
(Exact name of registrant as specified in its charter)
| | |
Delaware | | 38-4187694 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
Upstream Bio, Inc.
890 Winter Street, Suite 200
Waltham, MA 02451
(781) 208-2466
(Address, including zip code and telephone number, including area code, of registrant’s principal executive offices)
Upstream Bio, Inc. 2021 Stock Option and Grant Plan
Upstream Bio, Inc. 2024 Stock Option and Incentive Plan
Upstream Bio, Inc. 2024 Employee Stock Purchase Plan
(Full title of the plans)
E. Rand Sutherland, M.D., M.P.H.
Chief Executive Officer
890 Winter Street, Suite 200
Waltham, MA 02451
(781) 208-2466
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Gabriela Morales-Rivera
William D. Collins
Kathryn W. Clerici
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐